The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
暂无分享,去创建一个
Michael A Proschan | Philip Pallmann | Adrian P Mander | Thomas Jaki | Yuki Ando | Susan Todd | Christopher J Weir | James Wason | Douglas G Altman | Munyaradzi Dimairo | Daniel Hind | Toshimitsu Hamasaki | Elizabeth Coates | Steven A Julious | Marc K Walton | Katie Biggs | Franz Koenig | J. Wason | M. Proschan | S. Todd | D. Altman | J. Nicholl | T. Jaki | M. Dimairo | S. Julious | F. Koenig | C. Weir | E. Coates | T. Hamasaki | D. Hind | P. Pallmann | A. Mander | M. Walton | K. Biggs | Y. Ando | Jon P Nicholl | John A Scott
[1] Brenda Gaydos,et al. Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations , 2012, Journal of diabetes science and technology.
[2] Jay J H Park,et al. Critical concepts in adaptive clinical trials , 2018, Clinical epidemiology.
[3] P. Bauer,et al. Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.
[4] J. Kolesar,et al. A Bayesian adaptive design with biomarkers for targeted therapies , 2010, Clinical trials.
[5] Michael J. Rosenberg. The agile approach to adaptive research , 2010 .
[6] K. Gabriel,et al. On closed testing procedures with special reference to ordered analysis of variance , 1976 .
[7] G. Wassmer,et al. Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker , 2018, Statistical methods in medical research.
[8] L. Puljak,et al. Reporting quality of randomized controlled trial abstracts in the seven highest-ranking anesthesiology journals , 2018, Trials.
[9] U. Lorch,et al. Three steps to writing adaptive study protocols in the early phase clinical development of new medicines , 2014, BMC Medical Research Methodology.
[10] J. Wathen,et al. Adaptive Design: Results of 2012 Survey on Perception and Use , 2014, Therapeutic innovation & regulatory science.
[11] S. Pocock. Group sequential methods in the design and analysis of clinical trials , 1977 .
[12] M. Posch,et al. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency , 2018, Trials.
[13] Choi Sc,et al. Monitoring clinical trials based on predictive probability of significance. , 1989 .
[14] A. Grieve,et al. Response‐adaptive clinical trials: case studies in the medical literature , 2017, Pharmaceutical statistics.
[15] J. Lachin. A review of methods for futility stopping based on conditional power , 2005, Statistics in medicine.
[16] W. Brannath,et al. Exact Confidence Bounds Following Adaptive Group Sequential Tests , 2009, Biometrics.
[17] G. MacLennan,et al. Bayesian clinical trial designs: Another option for trauma trials? , 2017, The journal of trauma and acute care surgery.
[18] Martin Posch,et al. Design and estimation in clinical trials with subpopulation selection , 2018, Statistics in medicine.
[19] B. Chaitman,et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. , 2004, JAMA.
[20] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.
[21] W. Brannath,et al. Unblinded Adaptive Statistical Information Design Based on Clinical Endpoint or Biomarker , 2013 .
[22] S D Walter,et al. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility , 2017, Statistics in medicine.
[23] P. Gallo,et al. On the Optimal Timing of Futility Interim Analyses , 2017 .
[24] O. Keene,et al. Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group , 2006, Pharmaceutical statistics.
[25] A. Gould,et al. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance , 1992 .
[26] D. Jones,et al. Group sequential methods. , 1979, British Journal of Cancer.
[27] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[28] Adaptive Enrichment Designs for Stroke Clinical Trials. , 2017, Stroke.
[29] C. Berul,et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. , 2015, The New England journal of medicine.
[30] D. Altman,et al. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement , 2019, JAMA.
[31] Sue-Jane Wang,et al. Evaluation of the extent of adaptation to sample size in clinical trials for cardiovascular and CNS diseases. , 2018, Contemporary clinical trials.
[32] J. Hobart,et al. MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[33] W. Brannath,et al. Estimation in flexible two stage designs , 2006, Statistics in medicine.
[34] J. Lee,et al. An overview of the design and conduct of the BATTLE trials. , 2015, Chinese clinical oncology.
[35] B. Levin,et al. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop , 2012, Clinical trials.
[36] N Stallard,et al. Flexible sequential designs for multi‐arm clinical trials , 2014, Statistics in medicine.
[37] Christopher Jennison,et al. Analysis Following a Sequential Test , 1999 .
[38] S. Todd,et al. Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials , 2015, Trials.
[39] Lingyun Liu,et al. Adaptive Designs: Results of 2016 Survey on Perception and Use. , 2018, Therapeutic innovation & regulatory science.
[40] T. Jaki. Multi-arm clinical trials with treatment selection: what can be gained and at what price? , 2015 .
[41] D. Gordon,et al. Performance and predictors of recruitment success in National Heart, Lung, and Blood Institute’s cardiovascular clinical trials , 2018, Clinical trials.
[42] J. Whitehead,et al. Estimating a treatment effect in survival studies in which patients switch treatment , 2002, Statistics in medicine.
[43] Meinhard Kieser,et al. Blinded Sample Size Reestimation in Multiarmed Clinical Trials , 2000 .
[44] D. Ouellet. Benefit–risk assessment: the use of clinical utility index , 2010, Expert opinion on drug safety.
[45] Heinz Schmidli,et al. A practical guide to Bayesian group sequential designs , 2014, Pharmaceutical statistics.
[46] J. Ioannidis,et al. Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.
[47] Draft Guidance. Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE , 2010 .
[48] S. Heritier,et al. An adaptive confirmatory trial with interim treatment selection: Practical experiences and unbalanced randomization , 2011, Statistics in medicine.
[49] Frank Bretz,et al. Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls , 2015, Statistics in medicine.
[50] D. Altman. Comparability of Randomised Groups , 1985 .
[51] S. Senn. Testing for baseline balance in clinical trials. , 1994, Statistics in medicine.
[52] S. Pocock,et al. Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. , 2015, Journal of the American College of Cardiology.
[53] R. Kahn,et al. Outcome reporting bias in randomized-controlled trials investigating antipsychotic drugs , 2017, Translational Psychiatry.
[54] B. Turnbull,et al. Group Sequential Methods with Applications to Clinical Trials , 1999 .
[55] R. Emsley,et al. DELTA 2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial , 2018 .
[56] Tianjing Li,et al. CONSORT 2010 statement: extension to randomised crossover trials , 2019, BMJ.
[57] J. Ioannidis,et al. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias , 2008, PloS one.
[58] S. Lewis,et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials , 2017, JAMA.
[59] A. LaMarca,et al. Efficacy and Safety of Crofelemer for Noninfectious Diarrhea in HIV-Seropositive Individuals (ADVENT Trial): A Randomized, Double-Blind, Placebo-Controlled, Two-Stage Study , 2013, HIV clinical trials.
[60] Draft Guidance. Adaptive Designs for Clinical Trials of Drugs and Biologics , 2018 .
[61] M. García-Fiñana,et al. TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[62] R. Lewis. The pragmatic clinical trial in a learning health care system , 2016, Clinical trials.
[63] Philip Pallmann,et al. The R Package MAMS for Designing Multi-Arm Multi-Stage Clinical Trials , 2019, Journal of Statistical Software.
[64] A. Gould. Planning and revising the sample size for a trial. , 1995, Statistics in Medicine.
[65] Cyrus R Mehta,et al. Adaptive increase in sample size when interim results are promising: A practical guide with examples , 2011, Statistics in medicine.
[66] K. K. Lan,et al. Stochastically curtailed tests in long–term clinical trials , 1982 .
[67] Y H Joshua Chen,et al. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials , 2015, Clinical trials.
[68] Rong Tang,et al. Adaptive Design Practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013 , 2016, Therapeutic innovation & regulatory science.
[69] Nathaniel Katz,et al. Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial) , 2017, Pain.
[70] G. Wassmer,et al. Continuous Infusion of Clonidine in Ventilated Newborns and Infants: A Randomized Controlled Trial* , 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[71] S. Evans. When and How Can Endpoints Be Changed after Initiation of a Randomized Clinical Trial? , 2007, PLoS clinical trials.
[72] C. Mehta,et al. Exact inference for adaptive group sequential designs , 2013, Statistics in medicine.
[73] J. Wittes. Stopping a trial early – and then what? , 2012, Clinical trials.
[74] S. Ruberg,et al. Estimands in clinical trials – broadening the perspective , 2017, Statistics in medicine.
[75] J. Chien,et al. An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics , 2012, Journal of diabetes science and technology.
[76] W. Lehmacher,et al. Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.
[77] M. Proschan,et al. Designed extension of studies based on conditional power. , 1995 .
[78] Paul Gallo,et al. Sample Size Reestimation: A Review and Recommendations , 2006 .
[79] J. Lee,et al. Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development , 2016, Statistics in biosciences.
[80] T. Fleming,et al. Maintaining confidentiality of interim data to enhance trial integrity and credibility , 2008, Clinical trials.
[81] Jenny Y. Zhang,et al. Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study. , 2017, Contemporary clinical trials.
[82] B. Turnbull,et al. Adaptive sample size modification in clinical trials: start small then ask for more? , 2015, Statistics in medicine.
[83] Vladimir Dragalin,et al. Adaptive Designs: Terminology and Classification , 2006 .
[84] J. Herson. Coordinating Data Monitoring Committees and Adaptive Clinical Trial Designs , 2008 .
[85] M Kieser,et al. Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.
[86] S. Todd,et al. Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials , 2015, Trials.
[87] H. Hemilä. Citation bias in the CONSORT comments on blinding , 2010 .
[88] Thomas J. Santner,et al. Design of Experiments: Ranking and Selection , 1984 .
[89] S. Solomon,et al. The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease , 2011, Clinical trials.
[90] Qi Jiang,et al. DIA’s Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for “Less Well-understood” Adaptive Designs , 2017, Therapeutic innovation & regulatory science.
[91] Max E Valentinuzzi,et al. SAFETY AND EFFICACY , 2010 .
[92] M. García-Fiñana,et al. Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy , 2015, BMJ Open.
[93] Lisa V. Hampson,et al. Adaptive designs in clinical trials: why use them, and how to run and report them , 2018, BMC Medicine.
[94] Donald A. Berry,et al. Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .
[95] T. Friede,et al. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review , 2016, Journal of biopharmaceutical statistics.
[96] Noah Simon,et al. Inference for multimarker adaptive enrichment trials , 2017, Statistics in medicine.
[97] D. Berry,et al. Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study , 2015, Clinical research and regulatory affairs.
[98] S. Pocock,et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.
[99] New guidance to improve sample size calculations for trials: eliciting the target difference , 2018, Trials.
[100] Sue-Jane Wang,et al. Modification of Sample Size in Group Sequential Clinical Trials , 1999, Biometrics.
[101] W. Brannath,et al. Selection and bias—Two hostile brothers , 2009, Statistics in medicine.
[102] P. Glasziou,et al. Avoidable waste in the production and reporting of evidence , 2009 .
[103] V. Fowler,et al. Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[104] W. Brannath,et al. The advantages and disadvantages of adaptive designs for clinical trials. , 2004, Drug discovery today.
[105] Kristian Thorlund,et al. Key design considerations for adaptive clinical trials: a primer for clinicians , 2018, British Medical Journal.
[106] A. Brennan,et al. A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[107] P. Gallo. Confidentiality and Trial Integrity Issues for Adaptive Designs , 2006 .
[108] J. Whitehead,et al. A FORTRAN program for the design and analysis of sequential clinical trials. , 1983, Computers and biomedical research, an international journal.
[109] T. Fleming,et al. Parameter estimation following group sequential hypothesis testing , 1990 .
[110] J. Ajani,et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. , 1998, The New England journal of medicine.
[111] B. Muthén,et al. Adaptive designs for randomized trials in public health. , 2009, Annual review of public health.
[112] Michael Krams,et al. Implementing Adaptive Designs: Logistical and Operational Considerations , 2006 .
[113] M. D. de Boer,et al. Testing for baseline differences in randomized controlled trials: an unhealthy research behavior that is hard to eradicate , 2015, International Journal of Behavioral Nutrition and Physical Activity.
[114] W. Brannath,et al. Estimation in adaptive group sequential trials , 2011 .
[115] J. Chien,et al. Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD‐5) , 2014, Diabetes, obesity & metabolism.
[116] F. Bretz,et al. Estimands and Their Role in Clinical Trials , 2017 .
[117] D. Spiegelhalter,et al. Monitoring clinical trials: conditional or predictive power? , 1986, Controlled clinical trials.
[118] R. A. Parker. Testing for qualitative interactions between stages in an adaptive study , 2009, Statistics in medicine.
[119] P. Gallo,et al. Alternative Views On Setting Clinical Trial Futility Criteria , 2014, Journal of biopharmaceutical statistics.
[120] E. Cobo,et al. Are CONSORT checklists submitted by authors adequately reflecting what information is actually reported in published papers? , 2018, Trials.
[121] John Whitehead,et al. One‐ and two‐stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint , 2009, Statistics in medicine.
[122] C. Lloyd,et al. Accurate p‐values for adaptive designs with binary endpoints , 2017, Statistics in medicine.
[123] KyungMann Kim. Group Sequential Methods with Applications to Clinical Trials , 2001 .
[124] T. Friede,et al. Exploring changes in treatment effects across design stages in adaptive trials , 2009, Pharmaceutical statistics.
[125] J. Herson,et al. Predictive probability early termination plans for phase II clinical trials. , 1979, Biometrics.
[126] S. Chow,et al. On the Independence of Data Monitoring Committee in Adaptive Design Clinical Trials , 2012, Journal of biopharmaceutical statistics.
[127] J. S. D. Cani,et al. Group sequential designs using a family of type I error probability spending functions. , 1990, Statistics in medicine.
[128] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.
[129] C. Gamble,et al. Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis , 2013, BMJ Open.
[130] R. Porcher,et al. Adaptive methods: when and how should they be used in clinical trials? , 2011, Therapie.
[131] M D Hughes,et al. Practical problems in interim analyses, with particular regard to estimation. , 1989, Controlled clinical trials.
[132] D. Moher,et al. CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration , 2008, PLoS medicine.
[133] Yevgen Tymofyeyev,et al. A Review of Available Software and Capabilities for Adaptive Designs , 2014 .
[134] S D Walter,et al. Randomised trials with provision for early stopping for benefit (or harm): The impact on the estimated treatment effect , 2019, Statistics in medicine.
[135] J. Whitehead. Supplementary analysis at the conclusion of a sequential clinical trial. , 1986, Biometrics.
[136] M. Buyse,et al. On Stopping a Randomized Clinical Trial for Futility , 2012 .
[137] T. Hardy,et al. A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.
[138] CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2011, BMJ : British Medical Journal.
[139] M. Parmar,et al. Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).
[140] Martin Posch,et al. Testing and estimation in flexible group sequential designs with adaptive treatment selection , 2005, Statistics in medicine.
[141] B. Goldacre,et al. COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time , 2019, Trials.
[142] S. Todd,et al. An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review , 2015, PloS one.
[143] Qi Jiang,et al. Addressing Challenges and Opportunities of “Less Well-Understood” Adaptive Designs , 2017, Therapeutic innovation & regulatory science.
[144] M. Parmar,et al. Speeding up the Evaluation of New Agents in Cancer , 2008, Journal of the National Cancer Institute.
[145] C. Theuer,et al. An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[146] Peter G. Smith,et al. Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial , 2014, PLoS neglected tropical diseases.
[147] Judith Quinlan,et al. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development , 2010, Clinical trials.
[148] Shein-Chung Chow,et al. Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.
[149] J. Wason,et al. Optimal multistage designs for randomised clinical trials with continuous outcomes , 2011, Statistics in medicine.
[150] Yunyun Jiang,et al. Impact of adaptation algorithm, timing, and stopping boundaries on the performance of Bayesian response adaptive randomization in confirmative trials with a binary endpoint. , 2017, Contemporary clinical trials.
[151] A. Monto,et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[152] Cumberlege. Selective reporting? , 1991 .
[153] M. Chen,et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct , 2018, The New England journal of medicine.
[154] M. Stuschke,et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. , 2017, European journal of cancer.
[155] J. Whitehead. Overrunning and underrunning in sequential clinical trials. , 1992, Controlled Clinical Trials.
[156] G. Piaggio,et al. Consort 2010 statement: extension to cluster randomised trials , 2012, BMJ : British Medical Journal.
[157] T. Friede,et al. Sample size recalculation for binary data in internal pilot study designs , 2004 .
[158] L. Harvey,et al. Statistical testing for baseline differences between randomised groups is not meaningful , 2018, Spinal Cord.
[159] A. Kesselheim,et al. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov , 2018, BMJ Open.
[160] R. Porcher,et al. Avoidable waste of research related to inadequate methods in clinical trials , 2015, BMJ : British Medical Journal.
[161] C. Jennison,et al. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.
[162] Meinhard Kieser,et al. Sample Size Recalculation in Internal Pilot Study Designs: A Review , 2006, Biometrical journal. Biometrische Zeitschrift.
[163] D. Berry,et al. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.
[164] J. Lachin. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit , 2009, Clinical trials.
[165] S. Chow,et al. Statistical inference for cancer trials with treatment switching , 2005, Statistics in medicine.
[166] A. Großhennig,et al. No solution yet for combining two independent studies in the presence of heterogeneity , 2015, Statistics in medicine.
[167] M. Milićević,et al. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. , 2013, European journal of cancer.
[168] C. Gamble,et al. Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies , 2017, BMJ Open.
[169] M. Parmar,et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial , 2012, The Lancet. Oncology.
[170] Jack Bowden,et al. A multi-stage drop-the-losers design for multi-arm clinical trials , 2016, Statistical methods in medical research.
[171] A. Marshall,et al. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines , 2017, BMC Medical Research Methodology.
[172] B. Freidlin,et al. Stopping clinical trials early for benefit: impact on estimation , 2009, Clinical trials.
[173] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[174] S. Pocock,et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. , 2009, Pulmonary pharmacology & therapeutics.
[175] M. Proschan,et al. Unplanned adaptations before breaking the blind , 2012, Statistics in medicine.
[176] Yuanxin Rong. Regulations on Adaptive Design Clinical Trials , 2014 .
[177] R. Wears. Are we there yet? Early stopping in clinical trials. , 2015, Annals of emergency medicine.
[178] Sunil V. Rao,et al. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. , 2013, JAMA.
[179] Martin Posch,et al. Repeated confidence intervals for adaptive group sequential trials , 2007, Statistics in medicine.
[180] Sue-Jane Wang. Perspectives on the Use of Adaptive Designs in Clinical Trials. Part I. Statistical Considerations and Issues , 2010, Journal of biopharmaceutical statistics.
[181] Shein-Chung Chow,et al. Adaptive Design in Clinical Research: Issues, Opportunities, and Recommendations , 2006, Journal of biopharmaceutical statistics.
[182] Jason Y. Adams,et al. Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock , 2018, JAMA network open.
[183] J. Connor,et al. The platform trial: an efficient strategy for evaluating multiple treatments. , 2015, JAMA.
[184] P. Bauer,et al. Adaptive Two Stage Designs and the Conditional Error Function , 1999 .
[185] E. Russek-Cohen,et al. CBER’s Experience With Adaptive Design Clinical Trials , 2016, Therapeutic innovation & regulatory science.
[186] D. Sargent,et al. Clinical trial designs incorporating predictive biomarkers. , 2016, Cancer treatment reviews.
[187] A. Sato,et al. Practical characteristics of adaptive design in phase 2 and 3 clinical trials , 2018, Journal of clinical pharmacy and therapeutics.
[188] G. Guyatt,et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. , 2010, JAMA.
[189] M. Parmar,et al. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome , 2013, Trials.
[190] D. Moher,et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review , 2006, The Medical journal of Australia.
[191] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[192] Sue-Jane Wang,et al. Adaptive enrichment with subpopulation selection at interim: methodologies, applications and design considerations. , 2013, Contemporary clinical trials.
[193] Anastasios A. Tsiatis,et al. Flexible Sample Size Considerations Using Information-Based Interim Monitoring , 2001 .
[194] Andrew Stone,et al. When is a seamless study desirable? Case studies from different pharmaceutical sponsors , 2014, Pharmaceutical statistics.
[195] S. Berry,et al. Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.
[196] T. Friede,et al. A comparison of methods for adaptive sample size adjustment , 2001, Statistics in medicine.
[197] Bin Yao,et al. Group Sequential Methods and Software Applications , 2011 .
[198] A. Koch. Confirmatory Clinical Trials with an Adaptive Design , 2006, Biometrical journal. Biometrische Zeitschrift.
[199] T. Jaki. Designing Multi-arm Multi-stage Clinical Studies , 2014 .
[200] Thomas Jaki,et al. Optimal design of multi‐arm multi‐stage trials , 2012, Statistics in medicine.
[201] D. Berry,et al. Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project , 2016, Trials.
[202] M. Posch,et al. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency , 2014, Trials.
[203] J. Wason,et al. Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study , 2018, BMC Cardiovascular Disorders.
[204] S. Pocock,et al. Stopping rules and estimation problems in clinical trials. , 1988, Statistics in medicine.
[205] Frank Bretz,et al. Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts , 2006, Biometrical journal. Biometrische Zeitschrift.
[206] M. Parmar,et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial , 2012, Trials.
[207] M. Sabatine,et al. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. , 2012, American heart journal.
[208] S. Todd,et al. Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice , 2015, Trials.
[209] R. Chappell,et al. University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (morning panel discussion) , 2017, Clinical trials.
[210] G. Wassmer,et al. Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration , 2010, Journal of biopharmaceutical statistics.
[211] D. Angus,et al. Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial. , 2018, Annals of the American Thoracic Society.
[212] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[213] L. Mbuagbaw,et al. Does the medical literature remain inadequately described despite having reporting guidelines for 21 years? – A systematic review of reviews: an update , 2018, Journal of multidisciplinary healthcare.
[214] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[215] S. Goodman,et al. Quantifying over-estimation in early stopped clinical trials and the “freezing effect” on subsequent research , 2016, Clinical trials.
[216] C. Mehta,et al. Design and monitoring of multi‐arm multi‐stage clinical trials , 2017, Biometrics.
[217] D. Girling. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial , 2002, The Lancet.
[218] M. Dimairo,et al. Adaptive designs undertaken in clinical research: a review of registered clinical trials , 2016, Trials.
[219] G. Hommel. Adaptive Modifications of Hypotheses After an Interim Analysis , 2001 .
[220] D. Berry,et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[221] W. Rosenberger,et al. The theory of response-adaptive randomization in clinical trials , 2006 .
[222] D. Andersson,et al. Efficacy and safety , 2018 .
[223] P Bauer,et al. Application of Adaptive Designs – a Review , 2006, Biometrical journal. Biometrische Zeitschrift.
[224] S. Heritier,et al. The role of adaptive trial designs in drug development , 2017, Expert review of clinical pharmacology.
[225] Lisa V. Hampson,et al. Group sequential tests for delayed responses (with discussion) , 2013 .
[226] B. Hutton,et al. The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.
[227] J. Wason,et al. A Bayesian adaptive design for biomarker trials with linked treatments , 2015, British Journal of Cancer.
[228] C. Coffey,et al. Adaptive Clinical Trials , 2008, Drugs in R&D.
[229] Frank Bretz,et al. Adaptive designs for confirmatory clinical trials , 2009, Statistics in medicine.
[230] J. Wason,et al. Minimizing the Maximum Expected Sample Size in Two-Stage Phase II Clinical Trials with Continuous Outcomes , 2012, Journal of biopharmaceutical statistics.
[231] M. Dimairo. The Utility of Adaptive Designs in Publicly Funded Confirmatory Trials , 2016 .
[232] J. H. van der Lee,et al. A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials , 2009, BMC pediatrics.
[233] Thomas Jaki,et al. A Bayesian adaptive design for clinical trials in rare diseases , 2016, Comput. Stat. Data Anal..
[234] Yining Du,et al. Simulation study for evaluating the performance of response-adaptive randomization. , 2015, Contemporary clinical trials.
[235] C. Coffey,et al. Adaptive trial designs: a review of barriers and opportunities , 2012, Trials.
[236] Christy Chuang-Stein,et al. What should be the role of homogeneity testing in adaptive trials? , 2009, Pharmaceutical statistics.
[237] M. Kieser,et al. Point estimation in adaptive enrichment designs , 2017, Statistics in medicine.
[238] D. Moher,et al. CONSORT for reporting randomised trials in journal and conference abstracts , 2008, The Lancet.
[239] T. Fleming,et al. Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.
[240] Franck Pires Cerqueira,et al. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial , 2019, Therapeutic innovation & regulatory science.
[241] D. Gillen,et al. Frequentist evaluation of group sequential clinical trial designs , 2007, Statistics in medicine.
[242] Nigel Stallard,et al. An alternative method to analyse the biomarker‐strategy design , 2018, Statistics in medicine.
[243] Michael A. Proschan,et al. Statistical Monitoring of Clinical Trials: A Unified Approach , 2006 .
[244] E. Lindsay. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct , 2018 .
[245] R. Simes,et al. An improved Bonferroni procedure for multiple tests of significance , 1986 .
[246] S. Chow,et al. Statistical Consideration of Adaptive Methods in Clinical Development , 2005, Journal of biopharmaceutical statistics.
[247] G. Le Teuff,et al. Bayesian survival analysis in clinical trials: What methods are used in practice? , 2017, Clinical trials.
[248] S. C. Choi,et al. Monitoring clinical trials based on predictive probability of significance. , 1989, Biometrics.
[249] Wenle Zhao,et al. A surrogate-primary replacement algorithm for response-adaptive randomization in stroke clinical trials , 2017, Statistical methods in medical research.
[250] J. Adams,et al. Vitamin D therapy , 2008, Current osteoporosis reports.
[251] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[252] J. Cleveland,et al. Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[253] Thomas Jaki,et al. Some recommendations for multi-arm multi-stage trials , 2012, Statistical methods in medical research.
[254] R. Kay. Statistical Principles for Clinical Trials , 1998, The Journal of international medical research.
[255] D. Moher,et al. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. , 2001, JAMA.
[256] S. Solomon,et al. Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease , 2011, American Journal of Nephrology.
[257] M. Krams,et al. Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.
[258] R. Gesser,et al. A seamless Phase IIB/III adaptive outcome trial: Design rationale and implementation challenges , 2015, Clinical trials.
[259] D. Moher,et al. Guidance for Developers of Health Research Reporting Guidelines , 2010, PLoS medicine.
[260] R. Kolamunnage-Dona,et al. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review , 2016, PloS one.
[261] J. Lötvall,et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. , 2010, American journal of respiratory and critical care medicine.
[262] Frank Bretz,et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.
[263] M. Gosho,et al. Trends in study design and the statistical methods employed in a leading general medicine journal , 2018, Journal of clinical pharmacy and therapeutics.
[264] D. J. Bratton,et al. Design issues and extensions of multi-arm multi-stage clinical trials , 2015 .
[265] K. Togo,et al. Optimal Timing for Interim Analyses in Clinical Trials , 2013, Journal of biopharmaceutical statistics.
[266] Frank Bretz,et al. Adaptive Dunnett tests for treatment selection , 2008, Statistics in medicine.
[267] José Pinheiro,et al. Practical Considerations for Adaptive Trial Design and Implementation , 2014 .
[268] J. Whitehead,et al. A generalized Dunnett Test for Multi-arm Multi-stage Clinical Studies with Treatment Selection , 2012 .
[269] David Armstrong,et al. DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial , 2018, British Medical Journal.
[270] M. Parmar,et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols , 2017, Clinical trials.
[271] P. Bauer,et al. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications , 2014, Biometrical journal. Biometrische Zeitschrift.
[272] Gregory Campbell,et al. Similarities and Differences of Bayesian Designs and Adaptive Designs for Medical Devices: A Regulatory View , 2013 .
[273] S. Solomon,et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. , 2012, JAMA.
[274] J. Grimshaw,et al. Impact of CONSORT extension for cluster randomised trials on quality of reporting and study methodology: review of random sample of 300 trials, 2000-8 , 2011, BMJ : British Medical Journal.
[275] P. Bauer,et al. The reassessment of trial perspectives from interim data—a critical view , 2006, Statistics in medicine.
[276] David H. Miller,et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis , 2011, Multiple sclerosis.
[277] Yao-long Chen,et al. Avoidable waste in the production and reporting of evidence , 2009, The Lancet.
[278] D. DeMets,et al. Guidelines for Statistical Analysis Plans. , 2017, JAMA.
[279] J. Wason,et al. Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. , 2018, BMC medicine.
[280] Shein-Chung Chow,et al. Benefits, challenges and obstacles of adaptive clinical trial designs , 2011, Orphanet journal of rare diseases.
[281] Siegfried Kropf,et al. Clinical Trials with an Adaptive Choice of Hypotheses , 2001 .